Daptomycin: a new treatment for insidious infections due to gram-positive pathogens.
Daptomycin, a new lipopeptide antibiotic, is highly bactericidal against the majority of Gram-positive human pathogens, including methicillin-resistant (MRSA) and vancomycin-resistant enterococci. Its mechanism of action is unique resulting in the destruction of the membrane potential without lysing the cell wall. The mechanism of action of daptomycin, its antibacterial spectrum, the development of resistance and pre- and clinical studies are discussed in this review.
Cottagnoud
Philippe
P
Department of Internal Medicine, Inselspital, Bern, Switzerland. pcottagn@insel.ch
D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D017576:Daptomycin / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D015394:Molecular Structure
D000900:Anti-Bacterial Agents; D017576:Daptomycin